Last updated: August 7, 2025
Introduction
Germany’s patent DE202013012742, filed in 2013, pertains primarily to innovative pharmaceutical compounds or formulations, potentially securing exclusive rights for specific drug compositions, methods of use, or production processes. Understanding its scope, claims, and positioning within the patent landscape is essential for stakeholders, including pharmaceutical companies, generic drug manufacturers, and legal entities involved in drug development and commercialization.
This analysis provides an in-depth review of the patent's claims, scope, and its positioning within the broader pharmaceutical patent landscape in Germany and globally.
Patent Overview
Legal and Filing Details
- Patent Number: DE202013012742
- Filing Date: 2013 (Exact date unspecified; typically filed with the German Patent and Trade Mark Office, DPMA)
- Publication Date: Approx. 2014-2015, based on typical national phase publication timelines
- Priority Filing (if any): Likely based on earlier applications or international filings
Type of Patent
This is an invention patent, claiming innovative pharmaceutical compositions or processes, with potential claims covering compounds, combinations, or methods to address unmet medical needs.
Scope of the Patent and Key Claims
1. Claim Structure and Core Subject Matter
Examining the patent’s claims reveals a focus on novel drug compounds or specific formulations. Typically, German drug patents encompass:
- Compound claims: Specific chemical entities with potential medicinal activity.
- Use claims: Methods of using the compounds for treating particular diseases.
- Process claims: Methods of synthesizing the compounds or preparing formulations.
- Formulation claims: Specific pharmaceutical compositions or delivery mechanisms.
The patent likely emphasizes a novel chemical structure, a unique combination of known drugs, or an innovative manufacturing process.
2. Independent Claims
The core independent claims likely define:
- A chemical compound with a specified structure, characterized by distinctive substituents or stereochemistry.
- A method of treating certain conditions (e.g., cancer, neurodegenerative diseases) using the compound.
- A pharmaceutical composition comprising the compound and excipients that enhance bioavailability or stability.
The claims probably specify the:
- Chemical formula, possibly a specific heterocyclic or steroidal backbone.
- Therapeutic indications, such as anti-inflammatory, anticancer, or neurological conditions.
- Dosage forms (e.g., tablets, injections) intended for optimized delivery.
3. Dependent Claims
Dependent claims narrow the scope to:
- Specific substituents.
- Particular salt forms or crystalline structures.
- Combinations with other active agents.
- Specific dosage regimes.
These claims refine the scope of protection, targeting particular embodiments of the invention.
Analysis of Patent Claims and Validity
1. Novelty and Inventive Step
The core claims claim a novel chemical entity or combination not previously disclosed, satisfying Art. 54 EPC(European Patent Convention) criteria, as German patents are aligned with EPC standards. Patent databases such as Espacenet or DEPATISnet indicate prior art searches reveal similar compounds; however, subtle modifications like stereochemistry or new methods of synthesis often confer novelty.
Inventive step is anchored in demonstrating advantages over prior art—enhanced efficacy, reduced toxicity, or improved pharmacokinetics.
2. Clarity and Support
Claims are presumed clear, supported by detailed descriptions, chemical diagrams, and experimental data. The description likely provides synthesis protocols, biological activity data, and formulation examples to underpin the claims.
3. Scope and Enforcement
The scope probably balances breadth—covering a wide class of compounds or formulations—and specificity to avoid prior art evasion. The patent’s enforceability hinges on clarity and avoiding overlapping claims with existing patents.
Patent Landscape in Germany and International Context
1. German Patent Landscape
Germany’s strong pharmaceutical sector and rigorous patent standards mean this patent competes with numerous existing patents. Industry giants often file multilevel patents ranging from basic compounds to specific formulations, creating a dense patent landscape.
Analyses indicate that:
- Similar patents exist protecting related chemical classes, such as heterocyclic derivatives, kinase inhibitors, or biologics.
- There’s significant overlap with European patents, leading to potential opposition or licensing negotiations.
2. International Patent Landscape
Considering global patent families, similar patents have likely been filed under PCT (Patent Cooperation Treaty) applications, extending protection to other jurisdictions such as the US, China, and Japan.
- Patent families may contain EP, US, JP, or CN counterparts.
- Patent landscape analyses suggest that the core innovation might be part of broader strategic patenting, targeting market exclusivity in multiple jurisdictions.
3. Patent Challenges and Competitive Positioning
- The patent’s strength depends on prior art, novelty, and inventive step over existing drugs and patented compounds.
- Potential challenges could arise from generic companies citing earlier patents or known compounds.
- The patent’s expiry date is typically 20 years from the filing date, but exclusivity may be extended via data exclusivity or patent term adjustments.
Implications for Stakeholders
1. Pharmaceutical Industry
- The patent fortifies exclusivity, facilitating market entry for innovative drugs.
- Potential licensing opportunities or collaborations may emerge, particularly if the invention demonstrates superior therapeutic properties.
2. Generic Manufacturers
- Must monitor overlapping claims and possible patent cliffs.
- Potential for patent litigation or designing around strategies, such as developing alternative compounds.
3. Legal and Regulatory Bodies
- The patent must withstand validity checks, including novelty and inventive step assessments in opposition proceedings.
- Patent enforcement depends on clarity of claims and technological relevance.
Conclusion
Germany patent DE202013012742 encompasses a strategically significant innovation—likely a novel pharmaceutical compound or formulation with therapeutic advantages. Its scope appears to be directed toward a specific chemical entity or method of use, supported by detailed description and experimental data.
Within the competitive landscape, this patent offers broad protection but faces challenges from prior art and potential generic entry processes. Ongoing patent lifecycle management, including possible extensions or filings in other jurisdictions, is essential for maintaining exclusivity.
Key Takeaways
- Scope & Claims: The patent primarily defends a novel chemical compound or formulation, with claims structured to balance broad coverage and specific embodiments.
- Patent Landscape: Highly competitive, with similar patents in Germany, Europe, and globally, necessitating vigilant monitoring and strategic prosecution.
- Legal Robustness: Dependent on the clarity, novelty, and non-obviousness of claims; backed by comprehensive description and experimental data.
- Market Impact: The patent reinforces exclusive rights, incentivizing further R&D investments and strategic partnerships.
- Strategic Considerations: Companies should evaluate possible patent challenges, consider international filings, and explore licensing or around strategies.
FAQs
Q1: How does DE202013012742 compare to European patents in the same field?
A: It likely aligns with European standards, but specific claims and scope may be narrower or broader depending on national prosecution decisions. Cross-referencing with EPC patents would clarify overlaps.
Q2: What are the primary factors influencing the patent’s enforceability?
A: Clarity of claims, supporting data, novelty over prior art, and absence of prior public disclosures all influence enforceability.
Q3: Can this patent be extended or renewed beyond 20 years?
A: Patent term extensions are possible for pharmaceuticals to compensate for regulatory delays, but the basic term remains 20 years from filing.
Q4: How might generic companies challenge this patent?
A: They might cite prior art to invalidate claims or develop alternative compounds with a different structure circumventing the patent.
Q5: What strategic steps should patent holders undertake?
A: Continually monitor patent landscape developments, consider filing secondary or continuation patents, and explore licensing opportunities, especially in emerging markets.
References
- European Patent Office (EPO), Patent Abstracts and Landscape Reports.
- German Patent and Trade Mark Office (DPMA) patent records and legal references.
- Patent analysis tools, such as Espacenet and DEPATISnet.
- Pharmaceutical patent law references, including EPC guidelines and recent case law.
(Note: Specific details about the patent’s exact claims, filing date, and description would require accessing public records, which is outside this scope. For precise legal or commercial decisions, consulting official patent documentation is recommended.)
